SR One Capital Management, LP
In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 14, 2025), SR One Capital Management, LP reported 13 stock positions worth $461.4 million. Its top holding was Arcellx (ACLX) at 33.5% of the portfolio, followed by Ars Pharmaceuticals (SPRY, 15.2%) and Crispr Therapeutics (CRSP, 11.1%). Compared with Q1 2025, it opened 1 new position. The biggest buy was a new position in Oric Pharmaceuticals (ORIC).
- Most Recent 13F
- Q2 2026
- Location
- Redwood City, CA
- CIK
- 0001910264
- Portfolio Value
- $461.4M (Q2 2025)
- SEC Filing
- 0000950123-25-008422 ↗ filed Aug 14, 2025
Holdings Value
Holdings 13 stocks · $461.4M
| ACLX Arcellx Inc. | 33.49% | 2,346,630 | $154.5M | No change |
| SPRY Ars Pharmaceuticals Inc. | 15.18% | 4,012,903 | $70.0M | No change |
| CRSP Crispr Therapeutics AG | 11.06% | 1,048,951 | $51.0M | No change |
| ZBIO Zenas Biopharma Inc. | 10.32% | 4,911,539 | $47.6M | No change |
| ORIC Oric Pharmaceuticals Inc. | 9.93% | 4,514,929 | $45.8M | New |
| MLYS Mineralys Therapeutics Inc. | 9.17% | 3,127,933 | $42.3M | No change |
| DSGN Design Therapeutics Inc. | 4.77% | 6,526,476 | $22.0M | No change |
| OCS Oculis Holding AG | 1.36% | 322,500 | $6.3M | No change |
| ALMS Alumis Inc. | 1.27% | 1,959,896 | $5.9M | No change |
| NKTX Nkarta Inc. | 1.20% | 3,333,333 | $5.5M | No change |
| ORKA Oruka Therapeutics Inc. | 1.05% | 430,330 | $4.8M | No change |
| KALA Kala Bio Inc. | 0.62% | 598,940 | $2.9M | No change |
| ENGN Engene Holdings Inc. | 0.59% | 747,750 | $2.7M | No change |
Portfolio Sells Q1 2025 → Q2 2025
| None this quarter. | |||
Portfolio Buys Q1 2025 → Q2 2025
| ORIC Oric Pharmaceuticals Inc. | New | 9.93% | +9.93 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 15 | $1.0B | MANE, ZBIO, CRSP, AVLN, DSGN |
| Q1 2026 | 14 | $915.4M | ACLX, MANE, ZBIO, CRSP, DSGN |
| Q4 2025 | 13 | $706.4M | ZBIO, ACLX, CRSP, DSGN, MLYS |
| Q3 2025 | 12 | $691.4M | ACLX, CRSP, ZBIO, MLYS, ORIC |
| Q2 2025 | 13 | $461.4M | ACLX, SPRY, CRSP, ZBIO, ORIC |
| Q1 2025 | 12 | $389.3M | ACLX, SPRY, MLYS, ZBIO, CRSP |
| Q4 2024 | 11 | $410.1M | ACLX, SPRY, CRSP, DSGN, ZBIO |
| Q3 2024 | 11 | $498.7M | ACLX, ZBIO, SPRY, CRSP, DSGN |
| Q2 2024 | 9 | $319.4M | ACLX, CRSP, SPRY, ALMS, MLYS |
| Q1 2024 | 6 | $364.1M | ACLX, CRSP, SPRY, NKTX, DSGN |